Meeting Banner
Abstract #3008

Molecular imaging assessment of changes in tumor microenvironment in response to PEGPH20 treatment.

Yu Saida1, Tomohiro Seki1, Yasunori Otowa1, Shun Kishimoto1, Jisook Lee2, Kazutoshi Yamamoto1, Nallathamby Devasahayam1, Jeffery R. Brender1, and Murali C. Krishna1
1National Cancer Institute, Bethesda, MD, United States, 2Halozyme, San Diego, CA, United States

PEGylated human hyaluronidase (PEGPH20) enzymatically deplete tumor hyaluronan, and allows re-expansion of intra-tumor vasculature to increase the delivery of therapeutic molecules. The purpose of this study was to monitor physiologic and metabolic changes in pancreatic adenocarcinoma xenograft in response to PEGPH20 treatment by using multi-modal imaging methods including hyperpolarized 13C-MRI with [1-13C] pyruvate, EPRI, DCE-MRI, and photoacoustic imaging. Significantly decreased glycolysis, increased intratumor pO2, improved perfusion, and increased oxyhemoglobin saturation as well as increased blood volume, were observed after PEGPH20 treatment. The results validate the utility of these imaging methods to non-invasively monitor the PEGPH20-induced changes in the tumor microenvironment.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords